Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Entrada Therapeutics, Inc. - Common Stock (NQ:TRDA)

6.350 -0.040 (-0.63%)
Streaming Delayed Price Updated: 11:00 AM EDT, Jul 25, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Entrada Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 Next >
HC Wainwright & Co. Maintains Buy Rating for Entrada Therapeutics: Here's What You Need To Know
 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
 
Via Benzinga
Why Is Neuromuscular Disease Focused Entrada Therapeutics Shares Trading Lower Today?
Entrada Therapeutics Inc (NASDAQ: TRDA) shares are trading lower after the company announced updates on ENTR-601-44 in  
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
 
Via Benzinga
Entrada Therapeutics Announces Updates on ENTR-601-44 in Duchenne Muscular Dystrophy
From Entrada Therapeutics, Inc.
Via GlobeNewswire
Entrada Therapeutics Reports Third Quarter 2023 Financial Results
From Entrada Therapeutics, Inc.
Via GlobeNewswire
Entrada Therapeutics to Present at Upcoming Investor Conferences
From Entrada Therapeutics, Inc.
Via GlobeNewswire
Entrada Therapeutics Announces First Participant Dosed in its Phase 1 Clinical Trial of ENTR-601-44 for the Potential Treatment of Duchenne Muscular Dystrophy
From Entrada Therapeutics, Inc.
Via GlobeNewswire
Entrada Therapeutics Awards Funding to Non-Profit Organizations Advancing Diversity, Equity, Inclusion and Accessibility within the Duchenne Muscular Dystrophy Community
From Entrada Therapeutics, Inc.
Via GlobeNewswire
Entrada Therapeutics to Present at Upcoming Investor Conferences
From Entrada Therapeutics, Inc.
Via GlobeNewswire
Entrada Therapeutics Appoints Gina Chapman to its Board of Directors
From Entrada Therapeutics, Inc.
Via GlobeNewswire
Entrada Therapeutics Reports Second Quarter 2023 Financial Results
From Entrada Therapeutics, Inc.
Via GlobeNewswire
Entrada Therapeutics Receives Authorization in the United Kingdom to Initiate Phase 1 Clinical Trial of ENTR-601-44 for the Potential Treatment of Duchenne Muscular Dystrophy
From Entrada Therapeutics, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Monday's Intraday Session
 
Via Benzinga
Entrada Therapeutics to Present at Goldman Sachs 44th Annual Global Healthcare Conference
From Entrada Therapeutics, Inc.
Via GlobeNewswire
Vertex Pharmaceuticals Hits Record High on Strong Q1 Earnings
Vertex Pharmaceuticals hits record high on strong earnings, FDA approval for cystic fibrosis medication for infants. Analysts recently boosted price targets. 
Via MarketBeat
Entrada Therapeutics Reports First Quarter 2023 Financial Results
From Entrada Therapeutics, Inc.
Via GlobeNewswire
Entrada Therapeutics Appoints Dr. Bernhardt Zeiher to its Board of Directors
From Entrada Therapeutics, Inc.
Via GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For April 3, 2023
 
Via Benzinga
Entrada Therapeutics to Participate in Guggenheim Genomic Medicines and Rare Disease Conference
From Entrada Therapeutics, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Thursday's After-Market Session
 
Via Benzinga
Entrada Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results
From Entrada Therapeutics, Inc.
Via GlobeNewswire
Entrada Therapeutics to Participate in Cowen 43rd Annual Health Care Conference
From Entrada Therapeutics, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Thursday's Intraday Session
 
Via Benzinga
Why Sabre Are Trading Lower By 19%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Gainers Sera Prognostics, Inc. (NASDAQ: SERA) shares surged 63.4% to $2.11 after the company announced top-line data from the AVERT PRETERM TRIAL. 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
 
Via Benzinga
Entrada Therapeutics Closes Agreement with Vertex to Discover and Develop Endosomal Escape Vehicle-Therapeutics for Myotonic Dystrophy Type 1 (DM1)
From Entrada Therapeutics, Inc.
Via GlobeNewswire
Entrada Therapeutics Announces Clinical Candidate, ENTR-601-45, for the Potential Treatment of People Living with Duchenne Muscular Dystrophy who are Exon 45 Skipping Amenable
ENTR-601-45 Expands Entrada’s Commitment to the Duchenne Community by Advancing a Potential Treatment for People Living with Duchenne Who are Exon 45 Skipping Amenable 
From Entrada Therapeutics, Inc.
Via GlobeNewswire
Dow Jumps 150 Points; Crude Oil Rises 1%
U.S. stocks traded higher toward the end of trading, with the Dow Jones gaining around 150 points on Tuesday. 
Via Benzinga
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.